Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
Pulmonary arterial hypertension is a severe disease for which diagnosis often is delayed. Matrix metalloproteinases have been suggested to play a role in vascular remodeling and pulmonary hypertension development. Our aim was therefore to investigate the potential role of matrix metalloproteinases a...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-12-01
|
Series: | Pulmonary Circulation |
Online Access: | https://doi.org/10.1177/2045894019895414 |
id |
doaj-a8ff2f2ef26e45a0a551a538abfa472e |
---|---|
record_format |
Article |
spelling |
doaj-a8ff2f2ef26e45a0a551a538abfa472e2020-11-25T03:44:47ZengSAGE PublishingPulmonary Circulation2045-89402019-12-01910.1177/2045894019895414Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertensionMattias Arvidsson0Abdulla Ahmed1Habib Bouzina2Göran Rådegran3The Hemodynamic Lab, The Section for Heart Failure and Valvular Disease, VO Heart and Lung Medicine, Skåne University Hospital, Lund, SwedenThe Hemodynamic Lab, The Section for Heart Failure and Valvular Disease, VO Heart and Lung Medicine, Skåne University Hospital, Lund, SwedenThe Hemodynamic Lab, The Section for Heart Failure and Valvular Disease, VO Heart and Lung Medicine, Skåne University Hospital, Lund, SwedenThe Hemodynamic Lab, The Section for Heart Failure and Valvular Disease, VO Heart and Lung Medicine, Skåne University Hospital, Lund, SwedenPulmonary arterial hypertension is a severe disease for which diagnosis often is delayed. Matrix metalloproteinases have been suggested to play a role in vascular remodeling and pulmonary hypertension development. Our aim was therefore to investigate the potential role of matrix metalloproteinases as biomarkers in diagnosis and differentiation of pulmonary arterial hypertension in relation to various causes of dyspnea and pulmonary hypertension. Using proximity extension assays, 10 matrix metalloproteinases and associated proteins were analyzed in venous plasma from healthy controls (n = 20), as well as patients diagnosed with pulmonary arterial hypertension (n = 48), chronic thromboembolic pulmonary hypertension (n = 20), pulmonary hypertension due to heart failure with preserved (n = 33) or reduced (n = 36) ejection fraction, and heart failure with reduced ejection fraction and heart failure with preserved ejection fraction without pulmonary hypertension (n = 15). Plasma levels of matrix metalloproteinase-2, -7, -9, -12 and TIMP-4 were elevated (p < 0.01) in pulmonary arterial hypertension compared to controls. Plasma levels of matrix metalloproteinase-7 were furthermore lower (p < 0.0081) in pulmonary arterial hypertension than in all the other disease groups, but higher compared to controls (p < 0.0001). Receiver operating characteristic analysis of matrix metalloproteinase-7 resulted in sensitivity of 58.7% and a specificity of 83.3% for detecting pulmonary arterial hypertension among the other disease groups. Plasma matrix metalloproteinase-7 may provide a potential new diagnostic tool to differentiate pulmonary arterial hypertension from other causes of dyspnea, including heart failure with or without pulmonary hypertension and healthy controls. Matrix metalloproteinase-7 may furthermore be involved in the development of pulmonary hypertension and pulmonary arterial hypertension. Future studies investigating the clinical usefulness of matrix metalloproteinase-7 in the differentiation and earlier diagnosis of pulmonary arterial hypertension, as well as its relationship to pulmonary arterial hypertension pathogenesis, are encouraged.https://doi.org/10.1177/2045894019895414 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mattias Arvidsson Abdulla Ahmed Habib Bouzina Göran Rådegran |
spellingShingle |
Mattias Arvidsson Abdulla Ahmed Habib Bouzina Göran Rådegran Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension Pulmonary Circulation |
author_facet |
Mattias Arvidsson Abdulla Ahmed Habib Bouzina Göran Rådegran |
author_sort |
Mattias Arvidsson |
title |
Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension |
title_short |
Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension |
title_full |
Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension |
title_fullStr |
Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension |
title_full_unstemmed |
Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension |
title_sort |
matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension |
publisher |
SAGE Publishing |
series |
Pulmonary Circulation |
issn |
2045-8940 |
publishDate |
2019-12-01 |
description |
Pulmonary arterial hypertension is a severe disease for which diagnosis often is delayed. Matrix metalloproteinases have been suggested to play a role in vascular remodeling and pulmonary hypertension development. Our aim was therefore to investigate the potential role of matrix metalloproteinases as biomarkers in diagnosis and differentiation of pulmonary arterial hypertension in relation to various causes of dyspnea and pulmonary hypertension. Using proximity extension assays, 10 matrix metalloproteinases and associated proteins were analyzed in venous plasma from healthy controls (n = 20), as well as patients diagnosed with pulmonary arterial hypertension (n = 48), chronic thromboembolic pulmonary hypertension (n = 20), pulmonary hypertension due to heart failure with preserved (n = 33) or reduced (n = 36) ejection fraction, and heart failure with reduced ejection fraction and heart failure with preserved ejection fraction without pulmonary hypertension (n = 15). Plasma levels of matrix metalloproteinase-2, -7, -9, -12 and TIMP-4 were elevated (p < 0.01) in pulmonary arterial hypertension compared to controls. Plasma levels of matrix metalloproteinase-7 were furthermore lower (p < 0.0081) in pulmonary arterial hypertension than in all the other disease groups, but higher compared to controls (p < 0.0001). Receiver operating characteristic analysis of matrix metalloproteinase-7 resulted in sensitivity of 58.7% and a specificity of 83.3% for detecting pulmonary arterial hypertension among the other disease groups. Plasma matrix metalloproteinase-7 may provide a potential new diagnostic tool to differentiate pulmonary arterial hypertension from other causes of dyspnea, including heart failure with or without pulmonary hypertension and healthy controls. Matrix metalloproteinase-7 may furthermore be involved in the development of pulmonary hypertension and pulmonary arterial hypertension. Future studies investigating the clinical usefulness of matrix metalloproteinase-7 in the differentiation and earlier diagnosis of pulmonary arterial hypertension, as well as its relationship to pulmonary arterial hypertension pathogenesis, are encouraged. |
url |
https://doi.org/10.1177/2045894019895414 |
work_keys_str_mv |
AT mattiasarvidsson matrixmetalloproteinase7indiagnosisanddifferentiationofpulmonaryarterialhypertension AT abdullaahmed matrixmetalloproteinase7indiagnosisanddifferentiationofpulmonaryarterialhypertension AT habibbouzina matrixmetalloproteinase7indiagnosisanddifferentiationofpulmonaryarterialhypertension AT goranradegran matrixmetalloproteinase7indiagnosisanddifferentiationofpulmonaryarterialhypertension |
_version_ |
1724512723668041728 |